현명내과

의학적 검토: 정지인 내과 전문의 / 류마티스내과 분과전임의 (서울대학교병원 전임의 과정 수료 (2021-2024))

영남대학교 의과대학 내과학 석박사 수료

최종 업데이트: 2026-03-16

개요

만성폐쇄성폐질환(COPD, ICD-10: J44.1)은 비가역적 기류제한을 특징으로 하는 만성 호흡기 질환입니다. 전 세계 사망원인 3위이며, 흡연이 주요 원인의 80-90%를 차지합니다. 만성 기관지염과 폐기종이 중복되는 스펙트럼 질환입니다.

원인과 위험인자

분류세부 인자기전/특징
흡연능동/수동 흡연기도 염증, 폐실질 파괴 (가장 중요)
직업성 노출분진, 화학물질15-20%의 COPD와 관련
대기오염실내외 공기오염개발도상국에서 중요한 원인
유전Alpha-1 antitrypsin 결핍조기 발병 폐기종, 검사 권고

증상

진단

폐기능검사(필수)

기관지확장제 흡입 후 FEV1/FVC < 0.7이면 COPD 확진. GOLD 분류: FEV1 ≥80%(경증) → <30%(매우 중증).

GOLD ABE 평가

증상(CAT/mMRC)과 악화 빈도를 결합한 ABE 그룹 분류로 치료 전략을 결정합니다.

영상검사

흉부 CT로 폐기종 분포, 기관지확장증, 폐암 동반 여부를 평가합니다.

치료

금연

FEV1 감소 속도를 정상화하는 유일한 치료. 약물(바레니클린, NRT)과 상담 병행 시 성공률 증가.

흡입제 치료(GOLD 2023)

Group A: 단기 기관지확장제. Group B: LAMA 또는 LABA. Group E(악화 빈도↑): LAMA+LABA, 호산구≥300이면 ICS 추가. 삼중요법(LAMA+LABA+ICS)은 중증 악화 감소에 유의한 효과(IMPACT trial).

호흡재활

6-12주 프로그램으로 운동능력, 호흡곤란, 삶의 질 개선. 모든 증상적 COPD에 권고됩니다.

PubMed 근거 요약

GOLD 2023 보고서는 COPD 치료의 국제 표준으로, ABE 분류 기반 맞춤 치료를 권고합니다. IMPACT trial(Lipson et al., 2018, NEJM)에서 삼중요법(FF/UMEC/VI)이 이중요법 대비 중등도-중증 악화를 15-25% 감소시켰습니다.

현명신경외과 류마티스내과의 접근

현명신경외과 류마티스내과에서는 GOLD 가이드라인 기반 COPD 단계적 관리, 금연 상담, 흡입기 사용법 교육을 제공합니다. 류마티스 질환에 동반된 간질성 폐질환과의 감별에도 전문성을 갖추고 있습니다.

자주 묻는 질문

Q: COPD는 금연하면 좋아지나요?

A: 금연은 COPD 진행을 늦추는 가장 효과적인 방법입니다. 이미 손상된 폐 조직은 회복되지 않지만, 금연 후 폐기능 감소 속도가 정상인과 비슷하게 느려집니다.

Q: COPD 흡입기는 어떤 종류가 있나요?

A: 기관지확장제(LAMA, LABA)와 흡입스테로이드(ICS)가 주요 약제입니다. GOLD 가이드라인에 따라 증상과 악화 빈도에 따라 단독 또는 병합하여 사용합니다.

Q: COPD 환자는 독감 예방접종을 받아야 하나요?

A: 반드시 권장됩니다. 인플루엔자 백신(매년)과 폐렴구균 백신은 COPD 급성 악화와 입원을 유의하게 줄여줍니다. GOLD 가이드라인에서 강력히 권고하고 있습니다.

Q: COPD와 천식은 어떻게 구분하나요?

A: COPD는 40세 이후 흡연력이 있는 환자에서 비가역적 기류제한이 특징이고, 천식은 젊은 나이에 발생하며 가역적 기도폐쇄가 특징입니다. 폐기능검사에서 기관지확장제 반응으로 감별합니다.

참고 문헌

  1. Patel N (2024). An update on COPD prevention, diagnosis, and management: The 2024 GOLD Report.. Nurse Pract. DOI: 10.1097/01.NPR.0000000000000180
  2. Singh D, Stockley R, Anzueto A, et al (2025). GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.. Eur Respir J. DOI: 10.1183/13993003.01603-2024
  3. Fromer L, Cooper CB (2008). A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD.. Int J Clin Pract. DOI: 10.1111/j.1742-1241.2008.01807.x
  4. Irwin RS, French CL, Chang AB, et al (2018). Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report.. Chest. DOI: 10.1016/j.chest.2017.10.016
  5. Vestbo J, Hurd SS, Agustí AG, et al (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.. Am J Respir Crit Care Med. DOI: 10.1164/rccm.201204-0596PP
  6. Vogelmeier CF, Criner GJ, Martinez FJ, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.. Am J Respir Crit Care Med. DOI: 10.1164/rccm.201701-0218PP
  7. Halpin DMG, Celli BR, Criner GJ, et al (2019). The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries.. Int J Tuberc Lung Dis. DOI: 10.5588/ijtld.19.0397
  8. Mirza S, Clay RD, Koslow MA, et al (2018). COPD Guidelines: A Review of the 2018 GOLD Report.. Mayo Clin Proc. DOI: 10.1016/j.mayocp.2018.05.026
  9. Sehl J, O'Doherty J, O'Connor R, et al (2018). Adherence to COPD management guidelines in general practice? A review of the literature.. Ir J Med Sci. DOI: 10.1007/s11845-017-1651-7
  10. Cheng SL, Lin CH, Chu KA, et al (2021). Update on guidelines for the treatment of COPD in Taiwan using evidence and GRADE system-based recommendations.. J Formos Med Assoc. DOI: 10.1016/j.jfma.2021.06.007
  11. (2025). [Guidelines for the prevention and management of bronchial asthma (2024 edition)].. Zhonghua Jie He He Hu Xi Za Zhi. DOI: 10.3760/cma.j.cn112147-20241013-00601
  12. Ismaila AS, Haeussler K, Czira A, et al (2022). Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.. Adv Ther. DOI: 10.1007/s12325-022-02231-0
  13. Calzetta L, Cazzola M, Matera MG, et al (2019). Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.. Chest. DOI: 10.1016/j.chest.2018.12.016
  14. Yang M, Li Y, Jiang Y, et al (2023). Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.. Eur Respir J. DOI: 10.1183/13993003.00302-2022
  15. Oba Y, Keeney E, Ghatehorde N, et al (2018). Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.. Cochrane Database Syst Rev. DOI: 10.1002/14651858.CD012620.pub2
  16. Ferguson GT, Darken P, Ballal S, et al (2020). Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.. Adv Ther. DOI: 10.1007/s12325-020-01311-3
  17. Koarai A, Yamada M, Ichikawa T, et al (2022). Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis.. Respir Investig. DOI: 10.1016/j.resinv.2021.04.007
  18. Li Y, Li J, Yang H, et al (2025). Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials.. BMC Pulm Med. DOI: 10.1186/s12890-025-03823-6
  19. Rodrigo GJ, Price D, Anzueto A, et al (2017). LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.. Int J Chron Obstruct Pulmon Dis. DOI: 10.2147/COPD.S130482
  20. Gong Y, Sui Z, Lv Y, et al (2023). LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.. Eur J Clin Pharmacol. DOI: 10.1007/s00228-023-03543-y
  21. Koarai A, Yamada M, Ichikawa T, et al (2021). Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis.. Respir Res. DOI: 10.1186/s12931-021-01777-x
  22. Calzetta L, Di Marco F, Blasi F, et al (2019). Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.. Pulm Pharmacol Ther. DOI: 10.1016/j.pupt.2019.101855
  23. Aziz MIA, Tan LE, Wu DB, et al (2018). Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.. Int J Chron Obstruct Pulmon Dis. DOI: 10.2147/COPD.S173472
  24. Ko FW, Chan KP, Hui DS, et al (2016). Acute exacerbation of COPD.. Respirology. DOI: 10.1111/resp.12780
  25. MacLeod M, Papi A, Contoli M, et al (2021). Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact.. Respirology. DOI: 10.1111/resp.14041
  26. Wedzicha JA, Seemungal TA (2007). COPD exacerbations: defining their cause and prevention.. Lancet. DOI: 10.1016/S0140-6736(07)61382-8
  27. Singh D, Han MK, Hawkins NM, et al (2024). Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review.. Adv Ther. DOI: 10.1007/s12325-024-02855-4
  28. Hattab Y, Alhassan S, Balaan M, et al (2016). Chronic Obstructive Pulmonary Disease.. Crit Care Nurs Q. DOI: 10.1097/CNQ.0000000000000105
  29. Qian Y, Cai C, Sun M, et al (2023). Analyses of Factors Associated with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Review.. Int J Chron Obstruct Pulmon Dis. DOI: 10.2147/COPD.S433183
  30. Wedzicha JA, Miravitlles M, Hurst JR, et al (2017). Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.. Eur Respir J. DOI: 10.1183/13993003.00791-2016
  31. Halpin DMG, Criner GJ, Papi A, et al (2021). Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. DOI: 10.1164/rccm.202009-3533SO
  32. Adibi A, Sin DD, Safari A, et al (2020). The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study.. Lancet Respir Med. DOI: 10.1016/S2213-2600(19)30397-2
  33. Viniol C, Vogelmeier CF (2018). Exacerbations of COPD.. Eur Respir Rev. DOI: 10.1183/16000617.0103-2017
  34. Lamberton CE, Mosher CL (2024). Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness.. Respir Care. DOI: 10.4187/respcare.11541
  35. Jenkins AR, Burtin C, Camp PG, et al (2024). Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis.. Thorax. DOI: 10.1136/thorax-2023-220333
  36. Menson KE, Dowman L (2024). Pulmonary Rehabilitation for Diseases Other Than COPD.. J Cardiopulm Rehabil Prev. DOI: 10.1097/HCR.0000000000000915
  37. Chen X, Xu L, Li S, et al (2024). Efficacy of respiratory support therapies during pulmonary rehabilitation exercise training in chronic obstructive pulmonary disease patients: a systematic review and network meta-analysis.. BMC Med. DOI: 10.1186/s12916-024-03605-7
  38. Cai Y, Ren X, Wang J, et al (2024). Effects of Breathing Exercises in Patients With Chronic Obstructive Pulmonary Disease: A Network Meta-analysis.. Arch Phys Med Rehabil. DOI: 10.1016/j.apmr.2023.04.014
  39. Burge AT, Gadowski AM, Jones A, et al (2024). Breathing techniques to reduce symptoms in people with serious respiratory illness: a systematic review.. Eur Respir Rev. DOI: 10.1183/16000617.0012-2024
  40. Chung C, Lee JW, Lee SW, et al (2024). Clinical Efficacy of Mobile App-Based, Self-Directed Pulmonary Rehabilitation for Patients With Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis.. JMIR Mhealth Uhealth. DOI: 10.2196/41753
  41. Kizmaz E, Telli Atalay O, Çetin N, et al (2024). Virtual reality for COPD exacerbation: A randomized controlled trial.. Respir Med. DOI: 10.1016/j.rmed.2024.107696
  42. Zeng Y, Wu Q, Chen Y, et al (2024). Early comprehensive pulmonary rehabilitation for hospitalized patients with acute ex-acerbation of chronic obstructive pulmonary disease: a randomized controlled trial.. J Rehabil Med. DOI: 10.2340/jrm.v56.39953
  43. Gillan R, Bachtel G, Webber K, et al (2024). Osteopathic manipulative treatment for chronic inflammatory diseases.. J Evid Based Med. DOI: 10.1111/jebm.12590

본 콘텐츠는 의학 논문과 임상 가이드라인을 기반으로 작성되었으며, 개인의 의료 상황에 따라 다를 수 있습니다. 정확한 진단과 치료는 전문의 상담을 통해 결정하시기 바랍니다.